PhytoTech Medical Limited (ASX:PYL) is focused on the research and development of products for administering MGC, and new treatments utilising MGC therapeutic components for various medical conditions.
Phytotech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company today announces that it has entered into a Heads of Agreement (HOA) with Canigma A.L. Ltd, based in Israel, to develop a revolutionary capsule based vaporiser to administer medical cannabis.
PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company advises that the performance milestones attached to the Class A Performance Rights and Class B Performance Rights, which were based on share price hurdles have been achieved.
As Chairman of PhytoTech Medical Limited (ASX:PYL), and on behalf of my fellow directors, I would like to provide you with update on the Company and in particular, the recent events that have occurred since listing on the ASX, on 22 Jan 2015.
Phytotech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company and the first MGC company to list on the Australian Stock Exchange, is pleased to provide an update on the research and development of its MGC based therapeutic delivery systems for administering Medical Grade Cannabis (MGC).
PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company and the first MGC company to list on the Australian Stock Exchange, today announces that the research and development into its delivery systems for administering Medical Grade Cannabis (MGC) based therapeutic products has now commenced.
PhytoTech Medical Limited (ASX:PYL), wishes to advise that Ross Smith has resigned as a director effective immediately.
